StockData

Roivant Sciences vs Tonix Pharmaceuticals

ROIV and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ROIV and TNXP compare

Roivant Sciences is the larger company, worth 555 times as much as Tonix Pharmaceuticals ($28.0B against $50.4M).

Tonix Pharmaceuticals grew revenue faster over the last twelve months (196% versus −67.6% for Roivant Sciences).

Tonix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −549% compared with −3535% at Roivant Sciences.

Tonix Pharmaceuticals scores higher on the StockData Score (10 against 7 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricROIVTNXP
Size and price
Market cap$28.0B$50.4M
Share price$38.71$2.94
Change, 1 year90.8%−81.5%
Change, 5 years453%−100.0%
Beta (5Y)0.420.75
Employees721142
StockData Score
Total score710 (better)
Valuation score03 (better)
Growth score02 (better)
Performance score1 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S3712×1.7× (better)
P/B6.6×0.2× (better)
FCF yield−2.9% (better)−314%
Fair value–$16.91
Margin of safety–82.6%
Growth
Revenue growth (TTM)−67.6%196% (better)
Revenue growth, 5Y average−19.1%–
Profitability
Gross margin–83.8%
Operating margin−7915%−568% (better)
Net margin−3535%−549% (better)
FCF margin−10901%−543% (better)
Return on equity−6.2% (better)−81.8%
Return on invested capital−407%−298% (better)
Financial health
Debt / equity0.000.00
Current ratio16.72 (better)6.61
Altman Z-score44.02 (better)−5.42
Piotroski F-score26 (better)
Dividends and buybacks
Buyback yield–−427%
Shareholder yield0.00% (better)−427%
Ownership
Held by institutions78.1%54.6%
Held by insiders13.9%0.27%
Insider net buying, 12 months−$798M$479K (better)
Superinvestors holding1–
Short interest, % of float7.3%19.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.